Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Colorectal Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 59 articles:
HTML format
Text format



Single Articles


    September 2019
  1. YAEGER R, Kotani D, Mondaca S, Parikh AR, et al
    Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-2004.
    PubMed     Text format     Abstract available


    August 2019
  2. ANGELL HK, Bruni D, Barrett JC, Herbst R, et al
    The Immunoscore: Colon Cancer and Beyond.
    Clin Cancer Res. 2019 Aug 14. pii: 1078-0432.CCR-18-1851.
    PubMed     Text format     Abstract available


  3. LAZZARI L, Corti G, Picco G, Isella C, et al
    Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-18-3440.
    PubMed     Text format     Abstract available


    July 2019
  4. LEE DW, Han SW, Bae JM, Jang H, et al
    Tumor Mutation Burden and Prognosis in Colorectal Cancer Patients Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-1105.
    PubMed     Text format     Abstract available


  5. WILLIS JA, Overman MJ, Vilar E
    Mismatch repair-proficient colorectal cancer: finding the right TiME to respond.
    Clin Cancer Res. 2019 Jul 1. pii: 1078-0432.CCR-19-1447.
    PubMed     Text format     Abstract available


    June 2019
  6. LIEU CH, Golemis EA, Serebriiskii IG, Newberg JY, et al
    Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.
    Clin Cancer Res. 2019 Jun 26. pii: 1078-0432.CCR-19-0899.
    PubMed     Text format     Abstract available


  7. FREIRE VALLS A, Knipper K, Giannakouri E, Sarachaga V, et al
    VEGFR1(+) metastasis-associated macrophages contribute to metastatic angiogenesis and influence colorectal cancer patient outcome.
    Clin Cancer Res. 2019 Jun 25. pii: 1078-0432.CCR-18-2123.
    PubMed     Text format     Abstract available


    April 2019
  8. PISKOL R, Huw LY, Sergin I, Klijn C, et al
    A Clinical Applicable Gene Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
    Clin Cancer Res. 2019 Apr 19. pii: 1078-0432.CCR-18-3032.
    PubMed     Text format     Abstract available


  9. FENG Q, Chang W, Mao Y, He G, et al
    Tumor-associated macrophages as prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer.
    Clin Cancer Res. 2019 Apr 15. pii: 1078-0432.CCR-18-2076.
    PubMed     Text format     Abstract available


  10. WANG XC, Yue X, Zhang R, Liu TY, et al
    Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating non-homologous end joining repair.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3735.
    PubMed     Text format     Abstract available


  11. DIAZ-MAROTO NG, Sanz-Pamplona R, Berdiel-Acer M, Cimas FJ, et al
    Non-canonical TGFb pathway relieves the blockade of IL-1b/TGFb-mediated crosstalk between tumour and stroma: TGFBR1TAK1 inhibition in colorectal cancer.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3957.
    PubMed     Text format     Abstract available


  12. SCHIRRIPA M, Biason P, Lonardi S, Pella N, et al
    Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization.
    Clin Cancer Res. 2019 Apr 9. pii: 1078-0432.CCR-19-0311.
    PubMed     Text format     Abstract available


  13. ANANDAPPA G, Lampis A, Cunningham D, Khan KH, et al
    MicroRNA 31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-18-3769.
    PubMed     Text format     Abstract available


  14. MORRIS VK
    Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral.
    Clin Cancer Res. 2019;25:2030-2032.
    PubMed     Text format     Abstract available


    February 2019
  15. SIRAVEGNA G, Sartore-Bianchi A, Nagy RJ, Raghav K, et al
    Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-3389.
    PubMed     Text format     Abstract available


    January 2019
  16. OGAWA R, Yamamoto T, Hirai H, Hanada K, et al
    Loss of SMAD4 promotes colorectal cancer progression by recruiting tumor-associated neutrophils via CXCL1/8-CXCR2 axis.
    Clin Cancer Res. 2019 Jan 31. pii: 1078-0432.CCR-18-3684.
    PubMed     Text format     Abstract available


  17. TOKUNAGA R, Xiu J, Johnston C, Goldberg RM, et al
    Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer.
    Clin Cancer Res. 2019 Jan 28. pii: 1078-0432.CCR-18-3388.
    PubMed     Text format     Abstract available


    December 2018
  18. WASSERMAN I, Lee LH, Ogino S, Marco MR, et al
    SMAD4 loss in colorectal cancer patients correlates with recurrence, loss of immune infiltrate, and chemoresistance.
    Clin Cancer Res. 2018 Dec 26. pii: 1078-0432.CCR-18-1726.
    PubMed     Text format     Abstract available


  19. YANG W, Ma Y, Smith-Warner SA, Song M, et al
    Calcium intake and survival after colorectal cancer diagnosis.
    Clin Cancer Res. 2018 Dec 13. pii: 1078-0432.CCR-18-2965.
    PubMed     Text format     Abstract available


    November 2018
  20. PEETERS M, Price T, Boedigheimer M, Kim TW, et al
    Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Treated With Panitumumab in the ASPECCT Study.
    Clin Cancer Res. 2018 Nov 28. pii: 1078-0432.CCR-18-2072.
    PubMed     Text format     Abstract available


  21. PARK SY, Kim JY, Choi JH, Kim JH, et al
    Inhibition of LEF1-mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
    Clin Cancer Res. 2018 Nov 16. pii: 1078-0432.CCR-18-1232.
    PubMed     Text format     Abstract available


    October 2018
  22. LEE LY, Woolley CE, Starkey T, Biswas S, et al
    SERUM- AND GLUCOCORTICOID-INDUCED KINASE SGK1 DIRECTLY PROMOTES THE DIFFERENTIATION OF COLORECTAL CANCER CELLS AND RESTRAINS METASTASIS.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1033.
    PubMed     Text format     Abstract available


    September 2018
  23. PARIKH AR, Lee FC, Yau L, Koh H, et al
    MAVERICC, a randomized, biomarker-stratified, phase 2 study of mFOLFOX6-bevacizumab vs FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1221.
    PubMed     Text format     Abstract available


    August 2018
  24. LAURENT-PUIG P, Grisoni ML, Heinemann V, Liebaert F, et al
    Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1324.
    PubMed     Text format     Abstract available


  25. LEE V, Wang JS, Zahurak ML, Gootjes EC, et al
    A phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan.
    Clin Cancer Res. 2018 Aug 10. pii: 1078-0432.CCR-18-0421.
    PubMed     Text format     Abstract available


    June 2018
  26. PAAUWE M, Schoonderwoerd MJ, Helderman RFCPA, Harryvan TJ, et al
    Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-18-0329.
    PubMed     Text format     Abstract available


  27. GALLOIS C, Taieb J, Le Corre D, Le Malicot K, et al
    Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy.
    Clin Cancer Res. 2018 Jun 19. pii: 1078-0432.CCR-18-0866.
    PubMed     Text format     Abstract available


  28. BIAN Z, Zhang J, Li M, Feng Y, et al
    LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling.
    Clin Cancer Res. 2018 Jun 18. pii: 1078-0432.CCR-17-2967.
    PubMed     Text format     Abstract available


  29. KIM TW, Peeters M, Thomas AL, Gibbs P, et al
    Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer.
    Clin Cancer Res. 2018 Jun 13. pii: 1078-0432.CCR-17-3377.
    PubMed     Text format     Abstract available


    May 2018
  30. NODA M, Okayama H, Tachibana K, Sakamoto W, et al
    Glycosyltransferase gene expression identifies a poor prognostic colorectal cancer subtype associated with mismatch repair deficiency and incomplete glycan synthesis.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-17-3533.
    PubMed     Text format     Abstract available


  31. TOWNSEND A, Tebbutt NC, Karapetis CS, Cooper P, et al
    PHASE IB/II STUDY OF SECOND LINE THERAPY WITH PANITUMUMAB, IRINOTECAN AND EVEROLIMUS (PIE) IN KRAS WILD TYPE METASTATIC COLORECTAL CANCER.
    Clin Cancer Res. 2018 May 8. pii: 1078-0432.CCR-17-3590.
    PubMed     Text format     Abstract available


    April 2018
  32. RODRIGUEZ J, Vicent S, Chopitea A, Ponz-Sarvise M, et al
    Adjuvant therapy for colon cancer: genes, genes... and the patient in the center.
    Clin Cancer Res. 2018 Apr 20. pii: 1078-0432.CCR-18-0818.
    PubMed     Text format     Abstract available


    March 2018
  33. TOLEDO RA, Garralda E, Mitsi M, Pons T, et al
    Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of anti-angiogenic therapies.
    Clin Cancer Res. 2018 Mar 27. pii: 1078-0432.CCR-18-0103.
    PubMed     Text format     Abstract available


  34. MURCIA O, Jover R, Egoavil CM, Juarez M, et al
    TFAP2E Methylation and Expression Status Does Not Predict Response to 5FU-based Chemotherapy in Colorectal Cancer.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-2940.
    PubMed     Text format     Abstract available


  35. KANDIMALLA R, Gao F, Matsuyama T, Ishikawa T, et al
    Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-3236.
    PubMed     Text format     Abstract available


  36. HILL AG, Findlay M, Burge M, Jackson C, et al
    Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.
    Clin Cancer Res. 2018 Mar 5. pii: 1078-0432.CCR-17-0646.
    PubMed     Text format     Abstract available


    February 2018
  37. MESANGE P, Bouygues A, Ferrand N, Sabbah M, et al
    Combinations of Bevacizumab and Erlotinib show activity in colorectal cancer independent of RAS status.
    Clin Cancer Res. 2018 Feb 28. pii: 1078-0432.CCR-17-3187.
    PubMed     Text format     Abstract available


  38. HAYNES J, McKee TD, Haller AC, Wang Y, et al
    Administration of Hypoxia-Activated Prodrug Evofosfamide after Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Colorectal Cancer.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-1715.
    PubMed     Text format     Abstract available


  39. LI X, Wang Q, Gao X, Yu T, et al
    REGgamma controls Hippo signaling and reciprocal NF-kappaB-YAP regulation to promote colon cancer.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2986.
    PubMed     Text format     Abstract available


  40. LAMPRECHT S, Kaller M, Schmidt EM, Blaj C, et al
    PBX3 is part of an EMT regulatory network and indicates poor outcome in colorectal cancer.
    Clin Cancer Res. 2018 Feb 1. pii: 1078-0432.CCR-17-2572.
    PubMed     Text format     Abstract available


    January 2018

  41. Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
    Clin Cancer Res. 2018;24:499.
    PubMed     Text format    


  42. MARSHALL JF
    Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
    Clin Cancer Res. 2018;24:253-255.
    PubMed     Text format     Abstract available


    December 2017
  43. LIANG Q, Ma D, Zhu X, Wang Z, et al
    RING-finger protein 6 amplification activates JAK/STAT3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer.
    Clin Cancer Res. 2017 Dec 29. pii: 1078-0432.CCR-17-2133.
    PubMed     Text format     Abstract available


  44. DIENSTMANN R
    Tumor side as model of integrative molecular classification of colorectal cancer.
    Clin Cancer Res. 2017 Dec 21. pii: 1078-0432.CCR-17-3477.
    PubMed     Text format     Abstract available


  45. SVEEN A, Bruun J, Eide PW, Eilertsen IA, et al
    Colorectal cancer Consensus Molecular Subtypes translated to preclinical models uncover potentially targetable cancer-cell dependencies.
    Clin Cancer Res. 2017 Dec 14. pii: 1078-0432.CCR-17-1234.
    PubMed     Text format     Abstract available


  46. BERGER MD, Stintzing S, Heinemann V, Cao S, et al
    A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1663.
    PubMed     Text format     Abstract available


  47. ULINTZ PJ, Greenson JK, Wu R, Fearon ER, et al
    Lymph Node Metastases in Colon Cancer are Polyclonal.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-1425.
    PubMed     Text format     Abstract available


  48. CARNERO A, Lucena-Cacace A, Otero-Albiol D, Jimenez-Garcia MP, et al
    NAMPT is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and resistance to therapy through Sirt1 and PARP.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-2575.
    PubMed     Text format     Abstract available


    November 2017
  49. LOREE JM, Pereira AA, Lam M, Willauer AN, et al
    Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2484.
    PubMed     Text format     Abstract available


    October 2017
  50. GROTHEY A, Strosberg JR, Renfro LA, Hurwitz HI, et al
    A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Ontuxizumab (MORAb-004) in Patients with Chemorefractory Metastatic Colorectal Cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.1558.2017.
    PubMed     Text format     Abstract available


  51. LAL N, White BS, Goussous G, Pickles OJ, et al
    KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1090.2017.
    PubMed     Text format     Abstract available


  52. BOCCACCIO C, Luraghi P, Bigatto V, Cipriano E, et al
    A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.2151.2017.
    PubMed     Text format     Abstract available


    September 2017
  53. KANG DW, Lee BH, Suh YA, Choi YS, et al
    Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by Wnt/beta-catenin and PI3K/Akt Signaling.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0749.2017.
    PubMed     Text format     Abstract available


  54. JOUNG JG, Oh BY, Hong HK, AlKhalidi H, et al
    Tumor heterogeneity predicts metastatic potential in colorectal cancer.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0306.2017.
    PubMed     Text format     Abstract available


  55. YIN Y, Yao S, Hu Y, Feng Y, et al
    The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-derived IL-6.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1283.2017.
    PubMed     Text format     Abstract available


  56. BARTOLOME RA, Aizpurua C, Jaen M, Torres S, et al
    Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1444.2017.
    PubMed     Text format     Abstract available


  57. JIAO HL, Ye YP, Yang RW, Sun HY, et al
    Down-regulation of SAFB sustains the NF-kappaB pathway by targeting TAK1 during the progression of colorectal cancer.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0747.2017.
    PubMed     Text format     Abstract available


    March 2017
  58. PAKISH JB, Zhang Q, Chen Z, Liang H, et al
    Immune microenvironment in microsatellite instable endometrial cancers: Hereditary or sporadic origin matters.
    Clin Cancer Res. 2017 Mar 6. pii: clincanres.2655.2016.
    PubMed     Text format     Abstract available


  59. PICHLER M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, et al
    Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.
    Clin Cancer Res. 2017;23:1323-1333.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: